Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) was the target of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 62,600 shares, a decline of 21.6% from the May 15th total of 79,800 shares. Based on an average daily volume of 160,500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.7% of the shares of the company are short sold.
Monopar Therapeutics Stock Performance
MNPR stock traded up $0.03 during trading on Friday, hitting $0.94. The company had a trading volume of 117,140 shares, compared to its average volume of 178,243. The firm has a 50-day moving average price of $0.70 and a 200-day moving average price of $0.59. Monopar Therapeutics has a 1-year low of $0.27 and a 1-year high of $1.73.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. As a group, equities research analysts forecast that Monopar Therapeutics will post -0.37 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on Monopar Therapeutics
About Monopar Therapeutics
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Recommended Stories
- Five stocks we like better than Monopar Therapeutics
- Buy P&G Now, Before It Sets A New All-Time High
- MarketBeat Week in Review – 6/10 – 6/14
- How Technical Indicators Can Help You Find Oversold Stocks
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.